Alfred L. Garfall

Autologous Chimeric Antigen Receptor Engineered T Cell Immunotherapy for Desensitization in Patients Awaiting Kidney Transplantation

National Institute of Allergy and Infectious Diseases · U01

PI · $19.2M · University of Pennsylvania

Anti-Sox2 Immunotherapy to Prevent Multiple Myeloma Relapse

National Cancer Institute · R21

Contact PI · $423.9K · University of Pennsylvania

Limited-duration Teclistamab

Principal investigator · Recruiting · Phase 2

Abramson Cancer Center at Penn Medicine

Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma

Principal investigator · Completed · Phase 2

Medical College of Wisconsin

Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma

Principal investigator · Active not recruiting · Phase 1

University of Pennsylvania

Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple Myeloma

Principal investigator · Terminated · Early phase 1

Abramson Cancer Center at Penn Medicine